Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L.

The site is actively investigating cardiovascular diseases, focusing on conditions such as atherosclerotic cardiovascular disease, heart failure, and elevated lipoprotein(a). Trials aim to evaluate new therapies that lower risk of heart attacks, strokes, and cardiovascular death while also addressing related kidney and inflammatory complications.

• inclisiran for LDL‑cholesterol reduction
• evolocumab to prevent major adverse cardiovascular events
• pelacarsen targeting lipoprotein(a)
• retatrutide for combined cardiovascular and renal outcomes
• ziltivekimab addressing inflammation in ASCVD with chronic kidney disease

With 33 investigators and 56 active trials, the centre contributes robust data to improve prevention and treatment strategies for high‑risk patients across Europe.

Research in metabolic and nutritional diseases targets Type 2 Diabetes, obesity, and Type 1 Diabetes. The primary goal is to test innovative glucose‑lowering agents and weight‑management medicines that can improve glycaemic control and reduce cardiovascular complications.

• once‑weekly insulin icodec combined with insulin aspart for T1D
• semaglutide added to reduced‑dose basal insulin for T2D with overweight
• orforglipron for insulin‑treated Type 2 Diabetes
• retatrutide to lower serious heart‑related events in obesity

The department’s expertise in nutrition and metabolism supports the evaluation of therapies that address both blood sugar and body weight.

The centre conducts extensive studies on respiratory tract diseases, including asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. Trials seek to reduce exacerbations, improve lung function, and alleviate nasal symptoms through novel biologics and inhaled agents.

• CHF6001 as add‑on to triple therapy for COPD
• astigolimab to lower COPD exacerbation rates
• itepekimab for COPD and sinus opacification
• dupilumab to prevent lung‑function decline in uncontrolled asthma
• lebrikizumab to reduce nasal congestion and polyp size

These investigations aim to provide patients with more effective, personalized options for managing chronic airway diseases.

A broad portfolio addresses immune system diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, myasthenia gravis, and systemic sclerosis. The focus is on targeted antibodies and small molecules that modulate disease activity and improve quality of life.

• cenerimod for systemic lupus erythematosus
• ianalumab for Sjögren’s syndrome and lupus
• MB04 biosimilar compared with Enbrel in rheumatoid arthritis
• remibrutinib for chronic inducible urticaria
• IMVT‑1402 for ACPA‑positive rheumatoid arthritis

The trials combine safety monitoring with efficacy endpoints to advance treatment options for patients with complex autoimmune conditions.

Investigations into skin and connective tissue diseases concentrate on moderate to severe plaque psoriasis and chronic inducible urticaria. The objective is to assess the therapeutic benefit of novel biologics and small molecules in controlling skin inflammation and symptoms.

• ESK‑001 for moderate to severe plaque psoriasis
• remibrutinib versus placebo in chronic inducible urticaria
• lebrikizumab to improve nasal polyps associated with sinus disease

These studies aim to deliver faster, more durable relief for patients suffering from persistent dermatologic conditions.

The site also contributes to neoplasm research, particularly in head and neck squamous cell carcinoma. Trials evaluate innovative immunotherapy regimens designed to enhance anti‑tumor immunity and improve survival outcomes.

• novel immunotherapy combinations versus dostarlimab in PD‑L1‑positive recurrent/metastatic head and neck cancer

This work supports the development of next‑generation cancer treatments within the European clinical research network.